Asia stocks climb tracking Wall St rally; Nikkei hits record high, China GDP beats
Investing.com -- Recursion Pharmaceuticals executives discussed the company’s artificial intelligence-driven drug discovery platform during a Morgan Stanley webcast on Wednesday, detailing how the technology is being applied across target identification, molecule design and clinical development.
Chief Executive Najat Khan and Chief Financial Officer Ben Taylor outlined how Recursion uses machine learning combined with experimental biology to map genetic perturbations across biological systems. The company cited one mapping effort that identified 25 new targets simultaneously, compressing work that would traditionally require years of sequential research.
On molecule design, Recursion said it recently advanced a compound to clinical trials after designing approximately 330 molecules over 17 months, compared with industry norms of 2,500 to 5,000 compounds over four to five years. The company uses generative AI to optimize for potency, selectivity, safety and synthetic feasibility before laboratory synthesis.
Management said AI-driven approaches are already accelerating patient enrollment by 30% to 50% in clinical trials through improved recruitment and site selection. The company also applies AI to protocol design and patient stratification.
Recursion has assembled 40 petabytes of proprietary experimental data, supplemented by 25 additional petabytes through partnerships including one with Roche’s Genentech unit. Management said animal testing and related chemistry, manufacturing and controls work can represent roughly half the cost from initial concept to development candidate, an area where the company expects millions in savings as predictive models develop.
The executives noted that approved and late-stage drugs currently address only 10% of the genome, with clinical development consuming 70% of capital required for successful drug development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.